07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

BL-8020: Phase I/II started

BioLineRx began an open-label, French Phase I/II trial to evaluate once-daily 575 mg BL-8020 plus ribavirin for 16 weeks in up to 32 HCV patients who failed or relapsed following treatment with standard of care....
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

BL-8020: Phase I/II start

Next month, BioLineRx will begin an open-label, French Phase I/II trial to evaluate BL-8020 in patients who failed or relapsed following standard-of-care treatment. BioLineRx has exclusive, worldwide rights from Genoscience to BL-8020 under a 2012...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

BioLineRx, Genoscience, RFS deal

BioLineRx received exclusive, worldwide rights from Genoscience and RFS Pharma to BL-8030, an HCV NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. Genoscience and RFS Pharma,...
01:11 , Feb 7, 2012 |  BC Extra  |  Company News

BioLineRx in-licenses another HCV compound

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) announced a deal with Genoscience (Marseille, France) and RFS Pharma LLC (Tucker, Georgia) to in-license its second HCV compound in less than two weeks. BioLineRx received exclusive, worldwide rights to...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

BioLineRx, Genoscience deal

Genoscience granted BioLineRx exclusive, worldwide rights to preclinical oral HCV compound BL-8020. BioLineRx received an upfront payment and is eligible for milestones plus royalties. Details were not disclosed. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem,...
08:00 , Jan 30, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.03 to $0.77 last week after FDA extended the PDUFA date for an NDA for inhaled Adasuve Staccato loxapine by three months to May 4. According to Alexza,...
00:28 , Jan 25, 2012 |  BC Extra  |  Company News

BioLineRx soars on HCV deal

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) jumped $2.26 (69%) to $5.55 on Tuesday after Genoscience (Marseille, France) granted BioLineRx exclusive, worldwide rights to preclinical oral HCV compound BL-8020. According to Genoscience's website, the French company is...